Microbot Medical Inc.

As of March 31, 2026, Microbot Medical Inc carries a market capitalization of 139.69M, placing it among publicly traded companies globally. Its enterprise value stands at 77.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Microbot Medical Inc's next confirmed earnings release is scheduled for November 6, 2026.

As of March 31, 2026, Microbot Medical Inc has 67.16M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 1,253.12, and the price-to-book ratio stands at 2.18.

These figures are as of March 31, 2026. The EV/Sales ratio of 855.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 77.75M versus a market cap of 139.69M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Microbot Medical Inc maintains a current ratio of 22.59, meaning it holds 22.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Microbot Medical Inc posted a negative return on equity (ROE) of -27.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -26.09, reflecting losses generated across the asset base. The company generates approximately 2,838.61 in revenue per employee across its workforce of 32.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Microbot Medical Inc's stock has declined approximately 60.45% over the past 52 weeks. The 50-day moving average sits at 1.14, while the 200-day moving average is 1.62.

Over the twelve months ended March 31, 2026, Microbot Medical Inc generated 90,835.50 in revenue and converted that into -12.29M in net income, yielding earnings per share of -0.22. EBITDA reached -13.84M, while operating income came in at -13.88M.

As of March 31, 2026, Microbot Medical Inc holds 62.72M in cash and equivalents against 776,859.80 in total debt, resulting in a net debt position of -3.16M. Total book value stands at 64.11M, with working capital of 63.27M providing operational flexibility.

Microbot Medical Inc produced -13.17M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -134,090.50 in capital expenditures, free cash flow totaled -13.31M - equivalent to -0.24 per share.

These figures cover the twelve months ended March 31, 2026. The operating margin of -15,278.10 and net profit margin of -13,535.24 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -11.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -36.19, meaning Microbot Medical Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Microbot Medical Inc's most recent stock split took place on September 5, 2018 with a 15:1 split ratio.

As of March 31, 2026, Microbot Medical Inc has an Altman Z-Score of 22.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.